Physician profile
Donna P Ortiz
NPI 1114569431
$417,441.89
in general payments reported to CMS, 2019-2025
13 companies · $229K in 2025
The $229K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,127 · 2022: $34K · 2023: $58K · 2024: $92K · 2025: $229K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $283K · Travel and Lodging: $47K · Consulting Fee: $23K · Food and Beverage: $14K · Honoraria: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,099.36 |
| Travel and Lodging | $47,231.73 |
| Consulting Fee | $23,135.50 |
| Food and Beverage | $14,175.30 |
| Honoraria | $11,570.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $160,720.48 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $106,995.95 | 2021-2025 | |
| Lilly USA, LLC | $100,406.28 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $20,871.58 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $16,580.57 | 2024-2025 | Zymfentra, Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $4,178.65 | 2022-2025 | Entyvio, Gattex |
| Eli Lilly and Company | $3,331.91 | 2025 | Omvoh |
| Celgene Corporation | $2,194.66 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $2,030.53 | 2022-2025 | Stelara, Tremfya |
| Pfizer INC. | $64.51 | 2022-2025 | |
| Sandoz INC. | $24.55 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.40 | 2025 | Xifaxan |
| Ardelyx, INC. | $17.82 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.